1645



Patent Attorney's Docket No. <u>010830-116</u>

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

tent Application of	)				
e GUERIN-MARCHAND et al.	)	Group Art Unit: 1645			
tion No.: 09/837,344	)	Examiner: Patricia Ann D	uffy		
April 19, 2001	)	Confirmation No.: 2865	RECEIVED		
THE HEPATIC STAGE OF P.	)		JUL 2 8 2003		
	)		TECH CENTER 1600/2900		
			<u>EMENTS</u>		
ox 1450					
	n of	Species Requirements for the	e above-		
A Petition for Extension of Time is also	enc	closed.			
A Terminal Disclaimer and the [ ] \$55.0 C.F.R. § 1.20(d) are also enclosed.	00 (2	2814) [ ] \$110.00 (1814) fee d	ue under 37		
Also enclosed is					
Small entity status is hereby claimed.					
[ ] Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the [ ] \$375.00 (2801) [ ] \$750.00 (1801) fee due under 37 C.F.R. § 1.17(e).					
<ul> <li>Applicant(s) requests that any preventered. Continued examination is identified above.</li> </ul>	ious req	ly unentered after final amer uested based on the enclosed	ndments <u>not</u> be I documents		
[ ] Applicant(s) previously submitted requested.	,	on, for which continued	examination is		
	FALCIPARUM BEARING EPITOPES CAPABLE OF STIMULATING THE T LYMPHOCYTES  REPLY TO RESTRICTION AND ELECTOR TRANSMITT  ssioner for Patents ox 1450 dria, VA 22313-1450  closed is a Reply to Restriction and Electioned patent application.  A Petition for Extension of Time is also A Terminal Disclaimer and the [] \$55.0 C.F.R. § 1.20(d) are also enclosed.  Also enclosed is Small entity status is hereby claimed.  Applicant(s) requests continued examina [] \$375.00 (2801) [] \$750.00 (1801) f  [] Applicant(s) requests that any preventered. Continued examination is identified above.  [] Applicant(s) previously submitted.	tion No.: 09/837,344 )  April 19, 2001 )  PEPTIDE SEQUENCES SPECIFIC FOR ) THE HEPATIC STAGE OF P. ) FALCIPARUM BEARING EPITOPES ) CAPABLE OF STIMULATING THE T ) LYMPHOCYTES )  REPLY TO RESTRICTION AND ELECTIC TRANSMITTAL  ssioner for Patents ox 1450 dria, VA 22313-1450  closed is a Reply to Restriction and Election of ed patent application.  A Petition for Extension of Time is also ence deduction and Election of ed patent application.  A Terminal Disclaimer and the [ ] \$55.00 (2 C.F.R. § 1.20(d) are also enclosed.  Also enclosed is	de GUERIN-MARCHAND et al.   Group Art Unit: 1645    tion No.: 09/837,344   Examiner: Patricia Ann D  April 19, 2001   Confirmation No.: 2865    PEPTIDE SEQUENCES SPECIFIC FOR    THE HEPATIC STAGE OF P.    FALCIPARUM BEARING EPITOPES    CAPABLE OF STIMULATING THE T    LYMPHOCYTES   D  REPLY TO RESTRICTION AND ELECTION OF SPECIES REQUIRING TRANSMITTAL LETTER  ssioner for Patents    State of Patents    A Petition for Extension of Time is also enclosed.    A Petition for Extension of Time is also enclosed.    A Terminal Disclaimer and the [ ] \$55.00 (2814) [ ] \$110.00 (1814) fee de C.F.R. § 1.20(d) are also enclosed.    Also enclosed is		

Reply to Restriction and Election of Species Requirements Transmittal Letter Application No. <u>09/837,344</u>
Attorney's Docket No. <u>010830-116</u>
Page 2

[	] Applica	nt(s) requests s	uspension of	action by th	e Office until	at least,	which
	does no	t exceed three	months from	the filing of	this RCE, in	accordance	with
	37 C.F.	R. § 1.103(c).	The require	d fee under	37 C.F.R. §	1.17(i) is end	losed.

[ ] A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.12 TECEIVED (1809/2809) is also enclosed.

[X] No additional claim fee is required.

JUL 2 8 2003

[ ] An additional claim fee is required, and is calculated as shown below:

TECH CENTER 1600/2900

	No. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADD'L FEE
Total Claims	12	MINUS 20 =	-0-	× \$18.00 (1202) =	-0-
Independent Claims	3	MINUS 3 =	-0-	× \$84.00 (1201) =	-0-
If Amendment adds mu	ltiple depend	lent claims, add \$28	30.00 (1203)		
Total Claim Amendmer	ıt Fee				
If small entity status is	claimed, sub	tract 50% of Total	Claim Amend	ment Fee	

E	]	A total	fee in the	amount of \$	is	enclosed.
ſ	1	Charge	\$	to Deposit A	ccount No.	02-4800.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: July 24, 2003

Susan M. Dadio

Registration No. 40,373

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620



Attorney's Docket No. <u>010830-116</u>

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	`	$l \sim V$
in te ratent Application of	)	
Claudine GUERIN-MARCHAND et al.	)	Group Art Unit: 1645
Application No.: 09/837,344	)	Examiner: Patricia Ann Duffy
Filed: April 19, 2001	)	Confirmation No.: 2865
For: PEPTIDE SEQUENCES SPECIFIC	)	
FOR THE HEPATIC STAGE OF P.	)	JUL <b>2</b> 8 2003
FALCIPARUM BEARING	)	• • •
EPITOPES CAPABLE OF	)	TECH CENTER 1600/2900
STIMULATING THE T	)	IEOH OLIVIER 1000/1200

## REPLY TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

LYMPHOCYTES

Sir:

1

In complete response to the Official Action mailed on June 24, 2003, requiring restriction pursuant to 35 U.S.C. § 121, Applicants offer the following reply.

Applicants hereby elect, <u>with traverse</u>, to prosecute the invention of Group II, claims 31-38, drawn to polypeptides.

As provided in section 803 of the Manual of Patent Examining Procedure ("M.P.E.P."), there are two criteria for a proper requirement for restriction: (1) that inventions must be independent or distinct; and (2) there must be a serious burden on the Examiner if restriction is required. In this case, the restriction requirement is improper because at least the search and examination of all of the pending claims can be made

Application Serial No. <u>09/837,344</u> Attorney's Docket No. <u>010830-116</u>

Page 2

without serious burden. This is particularly so in light of the clearly close relationship between the subject matter of Groups I and II.

In any event, Applicants reserve the right to rejoin the claims of Group I, drawn to a process of using the elected polypeptides of Group II, at such time when the elected

polypeptide claims of Group II are found allowable. See M.P.E.P. § 821.04.

With regard to the election of species requirement, Applicants hereby elect, with traverse, SEQ ID NO: 41. Applicants believe that the claims based on SEQ ID NO: 41 should be considered together with those claims based on SEQ ID NO: 45. As can be seen from the sequence listing of the present application, the amino acid sequences of SEQ ID NO: 41 and SEO ID NO: 45 differ only in position 277.

In the event that there are any questions relating to this Reply to Restriction and Election of Species Requirements or the application in general, it would be appreciated if the Examiner would telephone the undersigned attorney concerning such questions so that prosecution of the application may be expedited.

Respectfully submitted,

Burns, Doane, Swecker & Mathis, L.L.P.

Susan M. Dadio

Registration No. 40,373

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: July 24, 2003

ì